Molecular aspects of allergens in atopic dermatitis

Current Opinion in Allergy and Clinical Immunology

Volumn 17, Issue 4, 2017, Pages 269-277

  Campana, Raffaela ^a   Dzoro, Sheron ^a   Mittermann, Irene ^a   Fedenko, Elena ^b   Elisyutina, Olga ^b   Khaitov, Musa ^b   Karaulov, Alexander ^c   Valenta, Rudolf ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INSTITUTE OF IMMUNOLOGY   (Russian Federation)

^c I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

allergen; allergen specific immunotherapy; atopic dermatitis; IgE associated allergy; micro arrayed allergens; molecular allergology; personalized medicine

Indexed keywords

ALLERGEN; BIOLOGICAL MARKER; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; RECOMBINANT ALLERGEN;

ALLERGY TEST; ANTIGEN FUNCTION; ATOPIC DERMATITIS; HUMAN; IMMUNOLOGY; IMMUNOREACTIVITY; IMMUNOTHERAPY; MOLECULAR DIAGNOSIS; MOLECULAR PATHOLOGY; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ANIMAL; PATHOLOGY; PROCEDURES;

ALLERGENS; ANIMALS; DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULIN E; PRECISION MEDICINE; T-LYMPHOCYTES;

EID: 85020521521     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000378     Document Type: Review

References (90)

1. Heratizadeh A. Atopic dermatitis: new evidence on the role of allergic inflammation. Curr Opin Allergy Clin Immunol 2016; 16:458-464.
2. Werfel T, Allam JP, Biedermann T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138:336-349.
3. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016; 387:1109-1122.
4. Wollenberg A, Oranje A, Deleuran M, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30:729-747.
5. Anto JM, Bousquet J, Akdis M, et al.Mechanisms of the development of allergy (MeDALL): introducing novel concepts in allergy phenotypes. J Allergy Clin Immunol 2017; 139:388-399.
6. Reginald K, Westritschnig K, Werfel T, et al. Immunoglobulin E antibody reactivity to bacterial antigens in atopic dermatitis patients. Clin Exp Allergy 2011; 41:357-369.
7. Reginald K, Westritschnig K, Linhart B, et al. Staphylococcus aureus fibronectin-binding protein specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for cellular immune responses. J Allergy Clin Immunol 2011; 128:82-91.e8.
8. Valenta R, Mittermann I,Werfel T, et al. Linking allergy to autoimmune disease. Trends Immunol 2009; 30:109-116.
9. Navarrete-Dechent C, Perez-Mateluna G, Silva-Valenzuela S, et al. Humoral and cellular autoreactivity to epidermal proteins in atopic dermatitis. Arch Immunol Ther Exp (Warsz) 2016; 64:435-442.
10. Campana R, Mothes N, Rauter I, et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 2008; 121:528-530.e1.
11. Campana R, Moritz K, Marth K, et al. Frequent occurrence of T cell-mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments. J Allergy Clin Immunol 2016; 137:601-609.e8.
12. Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2016; 138:1719-1722.e1.
13. Valenta R, Ferreira F, Focke-Tejkl M, et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28:211-241.
14. Valenta R, Campana R, Focke-Tejkl M, et al. Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol 2016; 137:351-357.
15. Valenta R, Campana R, Niederberger V. Recombinant allergy vaccines based on allergen-derived B cell epitopes. Immunol Lett 2017. [Epub ahead of print]
16. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189:1885-1894.
17. Werfel T, Heratizadeh A, Niebuhr M, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol 2015; 136:96-103.e9.
18. Reekers R, Busche M, Wittmann M, et al. Birch pollen-related foods trigger atopic dermatitis in patients with specific cutaneous T-cell responses to birch pollen antigens. J Allergy Clin Immunol 1999; 104 (2 Pt 1):466-472.
19. Roerdink EM, Flokstra-de Blok BM, Blok JL, et al. Association of food allergy and atopic dermatitis exacerbations. Ann Allergy Asthma Immunol 2016; 116:334-338.
20. Mittermann I, Wikberg G, Johansson C, et al. IgE sensitization profiles differ between adult patients with severe and moderate atopic dermatitis. PLoS One 2016; 11:e0156077.
21. Lucae S, Schmid-Grendelmeier P, Wuthrich B, et al. IgE responses to exogenous and endogenous allergens in atopic dermatitis patients under long-term systemic cyclosporine A treatment. Allergy 2016; 71:115-118.
22. Roesner LM, Heratizadeh A, Wieschowski S, et al. Alpha-NAC-specific autoreactive CD8+ T cells in atopic dermatitis are of an effector memory type and secrete IL-4 and IFN-gamma. J Immunol 2016; 196:3245-3252.
23. Werfel T, Morita A, Grewe M, et al. Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 1996; 107:871-876.
24. Hijnen D, Knol EF, Gent YY, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. J Invest Dermatol 2013; 133:973-979.
25. Hennino A, Vocanson M, Toussaint Y, et al. Skin-infiltrating CD8+ T cells initiate atopic dermatitis lesions. J Immunol 2007; 178:5571-5577.
26. Sehra S, Krishnamurthy P, Koh B, et al. Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation. Eur J Immunol 2016; 46:2609-2613.
27. Rivera A, Chen CC, Ron N, et al. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int Immunol 2001; 13:1583-1593.
28. Egbuniwe IU, Karagiannis SN, Nestle FO, et al. Revisiting the role of B cells in skin immune surveillance. Trends Immunol 2015; 36:102-111.
29. Cabauatan CR, Campana R, Niespodziana K, et al. Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination. Allergy 2017; 72:164-168.
30. Hirai T, Yoshioka Y, Takahashi H, et al. High-dose cutaneous exposure to mite allergen induces IgG-mediated protection against anaphylaxis. Clin Exp Allergy 2016; 46:992-1003.
31. Senti G, von Moos S, Tay F, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy 2015; 70:707-710.
32. Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper. Allergy 2017. [Epub ahead of print]
33. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, et al. EAACI molecular allergology user's guide. Pediatr Allergy Immunol 2016; 27 (Suppl 23):1-250.
34. Banerjee S, Resch Y, Chen KW, et al. Der p 11 is a major allergen for house dust mite-allergic patients suffering from atopic dermatitis. J Invest Dermatol 2015; 135:102-109.
35. Resch Y, Blatt K, Malkus U, et al. Molecular, structural and immunological characterization of Der p 18, a Chitinase-Like house dust mite allergen. PLoS One 2016; 11:e0160641.
36. Resch Y, Michel S, Kabesch M, et al. Different IgE recognition of mite allergen components in asthmatic and nonasthmatic children. J Allergy Clin Immunol 2015; 136:1083-1091.
37. Becker S, Schlederer T, Kramer MF, et al. Real-life study for the diagnosis of house dust mite allergy - the value of recombinant allergen-based ige serology. Int Arch Allergy Immunol 2016; 170:132-137.
38. Olivry T, Dunston SM, Favrot C, et al. The novel high molecular weight Dermatophagoides farinae protein Zen-1 is a major allergen in North American and European mite allergic dogs with atopic dermatitis. Vet Dermatol 2017; 28:e177-e238.
39. Gaitanis G, Magiatis P, Hantschke M, et al. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev 2012; 25:106-141.
40. Mothes N, Niggemann B, Jenneck C, et al. The cradle of IgE autoreactivity in atopic eczema lies in early infancy. J Allergy Clin Immunol 2005; 116:706-709.
41. Hennino A, Jean-Decoster C, Giordano-Labadie F, et al. CD8+ T cells are recruited early to allergen exposure sites in atopy patch test reactions in human atopic dermatitis. J Allergy Clin Immunol 2011; 127:1064-1067.
42. Lupinek C, Wollmann E, Baar A, et al. Advances in allergen-microarray technology for diagnosis and monitoring of allergy: the MeDALL allergenchip. Methods 2014; 66:106-119.
43. Westman M, Lupinek C, Bousquet J, et al. Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence. J Allergy Clin Immunol 2015; 135:1199-1206.e1-11.
44. Asarnoj A, Hamsten C, Waden K, et al. Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: a BAMSE/MeDALL study. J Allergy Clin Immunol 2016; 137:813-821.e7.
45. Asarnoj A, Hamsten C, Lupinek C, et al. Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: the BAMSE population-based birth cohort. J Allergy Clin Immunol 2017. [Epub ahead of print]
46. Posa D, Perna S, Resch Y, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol 2017; 139:541-549.e8.
47. Bousquet J, Anto JM, Wickman M, et al. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis. Allergy 2015; 70:1062-1078.
48. Foong RX, Roberts G, Fox AT, et al. Pilot study: assessing the clinical diagnosis of allergy in atopic children using a microarray assay in addition to skin prick testing and serum specific IgE. Clin Mol Allergy 2016; 14:8.
49. Gray CL, Levin ME, du Toit G. Egg sensitization, allergy and component patterns in African children with atopic dermatitis. Pediatr Allergy Immunol 2016; 27:709-715.
50. Fedenko E, Elisyutina O, Shtyrbul O, et al. Microarray-based IgE serology improves management of severe atopic dermatitis in two children. Pediatr Allergy Immunol 2016; 27:645-649.
51. McGhee SA. How the practice of allergy shows the promise and challenge of personalized medicine. Mol Genet Metab 2011; 104:3-6.
52. Riccio AM, De Ferrari L, Chiappori A, et al. Molecular diagnosis and precision medicine in allergy management. Clin Chem Lab Med 2016; 54:1705-1714.
53. Ferrando M, Bagnasco D, Varricchi G, et al. Personalized medicine in allergy. Allergy Asthma Immunol Res 2017; 9:15-24.
54. Marth K, Wollmann E, Gallerano D, et al. Persistence of IgE-associated allergy and allergen-specific IgE despite CD4+ T cell loss in AIDS. PLoS One 2014; 9:e97893.
55. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335-2348.
56. Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60:693-696.
57. Ruzicka T, Hanifin JM, Furue M, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 2017; 376:826-835.
58. Moreno AS, McPhee R, Arruda LK, et al. Targeting the T helper 2 inflammatory axis in atopic dermatitis. Int Arch Allergy Immunol 2016; 171:71-80.
59. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016; 15:35-50.
60. Kasperkiewicz M, Schmidt E, Frambach Y, et al. Improvement of treatmentrefractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 2011; 127:267-270, 70.e1-6.
61. Kasperkiewicz M, Sufke S, Schmidt E, et al. IgE-specific immunoadsorption for treatment of recalcitrant atopic dermatitis. JAMA Dermatol 2014; 150:1350-1351.
62. Daeschlein G, Scholz S, Lutze S, et al. Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis. Ther Apher Dial 2015; 19:279-287.
63. Reich K, Deinzer J, Fiege AK, et al. Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. J Allergy Clin Immunol 2016; 137:1882-1884.e6.
64. Zink A, Gensbaur A, Zirbs M, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol 2016; 96:72-76.
65. Incorvaia C, Riario-Sforza GG, Ridolo E. IgE depletion in severe asthma: what we have and what could be added in the near future. EBioMedicine 2017; 17:16-17.
66. Lupinek C, Derfler K, Lee S, et al. Extracorporeal IgE immunoadsorption in allergic asthma: safety and efficacy. EBioMedicine 2017; 17:119-133.
67. Thorsteinsdottir S, Thyssen JP, Stokholm J, et al.Domestic dog exposure at birth reduces the incidence of atopic dermatitis. Allergy 2016; 71:1736-1744.
68. Bremmer SF, Simpson EL. Dust mite avoidance for the primary prevention of atopic dermatitis: a systematic review and meta-analysis. Pediatr Allergy Immunol 2015; 26:646-654.
69. Ginsberg DN, Eichenfield LF. Debates in allergy medicine: specific immunotherapy in children with atopic dermatitis, the 'con' view. World Allergy Organ J 2016; 9:16.
70. Slavyanakaya TA, Derkach VV, Sepiashvili RI. Debates in allergy medicine: specific immunotherapy efficiency in children with atopic dermatitis. World Allergy Organ J 2016; 9:15.
71. Tam H, Calderon MA, Manikam L, et al. Specific allergen immunotherapy for the treatment of atopic eczema. Cochrane Database Syst Rev 2016; 2:Cd008774.
72. Shershakova N, Bashkatova E, Babakhin A, et al. Allergen-specific immunotherapy with monomeric allergoid in a mouse model of atopic dermatitis. PLoS One 2015; 10:e0135070.
73. Olivry T, Paps JS, Dunston SM. Proof of concept of the preventive efficacy of high-dose recombinant mono-allergen immunotherapy in atopic dogs sensitized to the Dermatophagoides farinae allergen Der f 2. Vet Dermatol 2017; 28:183-e40.
74. DeBoer DJ. The future of immunotherapy for canine atopic dermatitis: a review. Vet Dermatol 2017; 28:e25-e26.
75. Novak N, Thaci D, Hoffmann M, et al. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract - a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol 2011; 155:252-256.
76. Lee J, Lee H, Noh S, et al. Retrospective analysis on the effects of house dust mite specific immunotherapy for more than 3 years in atopic dermatitis. Yonsei Med J 2016; 57:393-398.
77. Cornelius C, Schoneweis K, Georgi F, et al. Immunotherapy with the PreSbased grass pollen allergy vaccine BM32 induces antibody responses protecting against hepatitis B infection. EBioMedicine 2016; 11:58-67.
78. Focke-Tejkl M, Weber M, Niespodziana K, et al. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol 2015; 135:1207-1217.e1-11.
79. Niederberger V, Marth K, Eckl-Dorna J, et al. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J Allergy Clin Immunol 2015; 136:1101-1103.e8.
80. Zieglmayer P, Focke-Tejkl M, Schmutz R, et al. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine 2016; 11:43-57.
81. Nomura T, Kabashima K. Advances in atopic dermatitis. J Allergy Clin Immunol 2016; 138:1548-1555.
82. Mudde GC, Hansel TT, von Reijsen FC, et al. IgE: an immunoglobulin specialized in antigen capture? Immunol Today 1990; 11:440-443.
83. Stingl G, Maurer D. IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int Arch Allergy Immunol 1997; 113:24-29.
84. Novak N, Bieber T, Kraft S. Immunoglobulin E-bearing antigen-presenting cells in atopic dermatitis. Curr Allergy Asthma Rep 2004; 4:263-269.
85. van Neerven RJ, Wikborg T, Lund G, et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 1999; 163:2944-2952.
86. Sae-Wong C, Mizutani N, Kangsanant S, et al. Topical skin treatment with Fab fragments of an allergen-specific IgG1 monoclonal antibody suppresses allergen-induced atopic dermatitis-like skin lesions in mice. Eur J Pharmacol 2016; 779:131-137.
87. Flicker S, Linhart B, Wild C, et al. Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. Immunobiology 2013; 218:884-891.
88. Freidl R, Gstoettner A, Baranyi U, et al. Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy. J Allergy Clin Immunol 2016. [Epub ahead of print]
89. Linhart B, Narayanan M, Focke-Tejkl M, et al. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy 2014; 44:278-287.
90. Madritsch C, Eckl-Dorna J, Blatt K, et al. Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers. J Allergy Clin Immunol 2015; 136:490-493.e11.